NSD-721 is the first drug candidate from the company's large research programme in the field of selective GABA receptor modulators, which have potential as anxiety-reducing drugs, but without the side effects known from existing drugs.
Results from a Phase I study show that the compound is safe and well tolerated and NeuroSearch is now evaluating the future development of NSD-721, including the compound's potential within psychiatric speciality indications.
